Faculty, Staff and Student Publications
Publication Date
10-1-2024
Journal
British Journal of Cancer
DOI
10.1038/s41416-024-02796-3
PMID
39048638
PMCID
PMC11405658
PubMedCentral® Posted Date
7-25-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Background: To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC).
Methods: COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (randomised; Part 2) trial in patients with treatment-naïve microsatellite stable mCRC. Patients in Part 2 were randomised to receive standard-of-care (control arm) or standard-of-care plus durvalumab and oleclumab (experimental arm). Primary objectives included safety and efficacy.
Results: Seven patients were enrolled in Part 1 and 52 in Part 2 (n = 26 in each arm). Grade ≥3 treatment-emergent adverse events (TEAE) occurred in 80.8% and 65.4% of patients in the control and experimental arms of Part 2, respectively, with 26.9% and 46.3% experiencing serious TEAEs. The confirmed objective response rate (ORR) was numerically higher in the experimental arm compared with the control arm (61.5% [95% confidence interval (CI), 40.6-79.8] vs 46.2% [95% CI, 26.6-66.6]) but did not meet the statistically significant threshold in either arm.
Conclusion: The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC.
Keywords
Humans, Colorectal Neoplasms, Female, Male, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Middle Aged, Aged, Adult, Antibodies, Monoclonal, Leucovorin, Fluorouracil, Organoplatinum Compounds, Neoplasm Metastasis, Aged, 80 and over
Published Open-Access
yes
Recommended Citation
Segal, Neil H; Tie, Jeanne; Kopetz, Scott; et al., "Columbia-1: A Randomised Study of Durvalumab Plus Oleclumab in Combination With Chemotherapy and Bevacizumab in Metastatic Microsatellite-Stable Colorectal Cancer" (2024). Faculty, Staff and Student Publications. 4626.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4626
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons
Comments
Registration: NCT04068610.